Fuan Pharmaceutical Group Co (300194) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fuan Pharmaceutical Group Co (300194) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥100.27 Million ≈ $14.67 Million USD) by net assets (CN¥4.45 Billion ≈ $651.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Fuan Pharmaceutical Group Co - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Fuan Pharmaceutical Group Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 300194 total liabilities for a breakdown of total debt and financial obligations.
Fuan Pharmaceutical Group Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fuan Pharmaceutical Group Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AGF Management Limited
F:A3J
|
0.037x |
|
Canny Elevator Co Ltd
SHE:002367
|
0.061x |
|
Multi Bintang Indonesia Tbk
JK:MLBI
|
0.329x |
|
Guangdong Piano Customized Furniture Co Ltd
SHE:002853
|
0.016x |
|
Lions Gate Entertainment Corp
NYSE:LGF-A
|
0.760x |
|
Tigerair Taiwan Co. Ltd.
TW:6757
|
0.334x |
|
Taewoong Co.Ltd
KQ:044490
|
-0.003x |
|
Dakota Gold Corp.
NYSE MKT:DC
|
-0.063x |
Annual Cash Flow Conversion Efficiency for Fuan Pharmaceutical Group Co (2007–2024)
The table below shows the annual cash flow conversion efficiency of Fuan Pharmaceutical Group Co from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see 300194 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥4.40 Billion ≈ $643.58 Million |
CN¥303.59 Million ≈ $44.42 Million |
0.069x | -12.95% |
| 2023-12-31 | CN¥4.15 Billion ≈ $607.09 Million |
CN¥328.98 Million ≈ $48.14 Million |
0.079x | -7.82% |
| 2022-12-31 | CN¥3.95 Billion ≈ $577.49 Million |
CN¥339.50 Million ≈ $49.68 Million |
0.086x | +29.34% |
| 2021-12-31 | CN¥3.87 Billion ≈ $565.70 Million |
CN¥257.13 Million ≈ $37.63 Million |
0.067x | +86.38% |
| 2020-12-31 | CN¥4.56 Billion ≈ $666.55 Million |
CN¥162.55 Million ≈ $23.79 Million |
0.036x | -51.84% |
| 2019-12-31 | CN¥3.99 Billion ≈ $583.77 Million |
CN¥295.63 Million ≈ $43.26 Million |
0.074x | +2.27% |
| 2018-12-31 | CN¥3.69 Billion ≈ $540.55 Million |
CN¥267.68 Million ≈ $39.17 Million |
0.072x | -33.34% |
| 2017-12-31 | CN¥4.17 Billion ≈ $610.29 Million |
CN¥453.37 Million ≈ $66.34 Million |
0.109x | +15.16% |
| 2016-12-31 | CN¥3.96 Billion ≈ $580.00 Million |
CN¥374.16 Million ≈ $54.75 Million |
0.094x | +25.23% |
| 2015-12-31 | CN¥2.14 Billion ≈ $312.59 Million |
CN¥161.03 Million ≈ $23.56 Million |
0.075x | +511.64% |
| 2014-12-31 | CN¥1.71 Billion ≈ $249.86 Million |
CN¥-31.27 Million ≈ $-4.58 Million |
-0.018x | -135.25% |
| 2013-12-31 | CN¥1.72 Billion ≈ $252.41 Million |
CN¥89.61 Million ≈ $13.11 Million |
0.052x | +42.41% |
| 2012-12-31 | CN¥1.72 Billion ≈ $251.77 Million |
CN¥62.77 Million ≈ $9.18 Million |
0.036x | -4.80% |
| 2011-12-31 | CN¥1.69 Billion ≈ $247.66 Million |
CN¥64.85 Million ≈ $9.49 Million |
0.038x | -89.82% |
| 2010-12-31 | CN¥281.05 Million ≈ $41.13 Million |
CN¥105.74 Million ≈ $15.47 Million |
0.376x | -2.08% |
| 2009-12-31 | CN¥163.31 Million ≈ $23.90 Million |
CN¥62.75 Million ≈ $9.18 Million |
0.384x | -13.55% |
| 2008-12-31 | CN¥110.76 Million ≈ $16.21 Million |
CN¥49.23 Million ≈ $7.20 Million |
0.444x | -80.47% |
| 2007-12-31 | CN¥8.31 Million ≈ $1.22 Million |
CN¥18.92 Million ≈ $2.77 Million |
2.276x | -- |
About Fuan Pharmaceutical Group Co
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China. It offers APIs; intermediates; and FFPs, such as anti-tumor, generic drugs, antibiotics and oral, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd. and… Read more